论文部分内容阅读
Vyvanse(lisdexamfetamine di mesylate)是由Shire公司与New River Pharma公司合作开发的苯丙胺衍生物。该药于2007年2月获美国FDA批准,用于治疗6~12岁儿童注意力缺陷和多动障碍(attention-deficit/hyperactivi-ty disorder ADHD)。Vyvanse的中文化学名称为:L-赖氨酸-d-苯丙胺
Vyvanse (lisdexamfetamine di mesylate) is a amphetamine derivative developed by Shire in collaboration with New River Pharma. The drug was approved by the U.S. FDA in February 2007 for the treatment of attention-deficit / hyperactivi-ty disorder (ADHD) in children aged 6 to 12 years. Vyvanse’s Chinese chemical name is: L-lysine-d-amphetamine